These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19406029)

  • 1. Benefits of luteinizing hormone activity in ovarian stimulation for IVF.
    Venetis CA; Kolibianakis EM; Tarlatzi TB; Tarlatzis BC
    Reprod Biomed Online; 2009; 18 Suppl 2():31-6. PubMed ID: 19406029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the combination of recombinant follicle-stimulating hormone and recombinant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis.
    Wang Y; Li L; Deng K; Liu J; Liu Y; Zou K; Hao G; Sun X
    J Evid Based Med; 2020 Aug; 13(3):215-226. PubMed ID: 32627395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying real differences in live birth rates between HMG and rFSH in IVF.
    Afnan M
    Reprod Biomed Online; 2009; 18 Suppl 2():25-30. PubMed ID: 19406028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of controlled ovarian stimulation for ART in poor responders according to the short protocol using different gonadotrophins combinations.
    Loutradis D; Elsheikh A; Kallianidis K; Drakakis P; Stefanidis K; Milingos S; Michalas S
    Arch Gynecol Obstet; 2004 Dec; 270(4):223-6. PubMed ID: 13680266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?
    Kirshenbaum M; Gil O; Haas J; Nahum R; Zilberberg E; Lebovitz O; Orvieto R
    Reprod Biol Endocrinol; 2021 Dec; 19(1):182. PubMed ID: 34886872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?
    Samara N; Reis D; Danielli Miller N; Ghetler Y; Berkovitz A; Miller M; Gonen O; Shulman A; Wiser A
    Gynecol Endocrinol; 2015; 31(11):877-9. PubMed ID: 26416777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fertilisation. A review of drug therapy and clinical management.
    Jennings JC; Moreland K; Peterson CM
    Drugs; 1996 Sep; 52(3):313-43. PubMed ID: 8875126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone.
    Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Ferlini F; Perri T; Parmegiani L
    Fertil Steril; 2003 Aug; 80(2):390-7. PubMed ID: 12909504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.
    Daya S; Gunby J; Hughes EG; Collins JA; Sagle MA
    Hum Reprod; 1995 Jun; 10(6):1392-6. PubMed ID: 7593503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.